How M.D. was paid
$7M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.
Named executive officers
| Executive | Salary | Stock | Options | Incentive | Other | Total |
|---|---|---|---|---|---|---|
| Marshall Fordyce, M.D.President and Chief Executive Officer | $660,000 | $2,356,285 | $3,415,725 | $554,400 | — | $6,986,410 |
| Sean GrantChief Financial Officer | $507,000 | $784,942 | $1,137,870 | $283,920 | $3,000 | $2,716,732 |
| David JohnsonChief Operating Officer | $510,000 | $784,942 | $1,137,870 | $285,600 | $3,000 | $2,721,412 |
| Robert Brenner, M.D.Chief Medical Officer | $509,000 | $784,942 | $1,137,870 | $285,040 | $3,000 | $2,719,852 |
| William TurnerChief Regulatory Officer | $473,000 | $656,550 | $951,750 | $264,880 | — | $2,346,180 |
What changed and why
- $7MMarshall Fordyce received total compensation of $6,986,410 in fiscal 2025, reflecting an increase from the prior year.
- $554KNon-equity incentive plan compensation for the CEO was $554,400 based on performance.
- $2.4MStock awards totaled $2,356,285 and option awards totaled $3,415,725 for the CEO in fiscal 2025.
- 97%Stockholders showed strong support with approximately 97% of votes cast in favor of the say-on-pay proposal.
About this page
Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.